RANCHO CORDOVA, Calif.,
July 23, 2019 /PRNewswire/
-- ThermoGenesis, a wholly owned subsidiary of Cesca
Therapeutics (Nasdaq: KOOL) and a market leader in automated
cellular processing, today announced that CBR® (Cord
Blood Registry), the country's largest newborn stem cell storage
bank has begun the process to transition to ThermoGenesis'
next-generation AXP® II System for the rapid processing
of cord blood units. ThermoGenesis continues to be CBR's sole
supplier of critical devices and disposables used in the processing
of cord blood samples, under an exclusive Manufacturing and Supply
Agreement which was entered into for the original AXP System in
2006.
"Having used our AXP System exclusively for the last 13 years,
the team at CBR understands our strong commitment to meeting the
unique needs of the cord blood banking industry," noted
Haihong Zhu, President of
ThermoGenesis. "We are very pleased to continue our work with this
world-class institution, as it begins utilizing the improved,
next-generation AXP II for processing of its clients' cord blood,
in addition to the organizations' important, ongoing clinical
research needs in regenerative medicine. We remain attuned to the
ever-changing demands required by the market and look forward to
further demonstrating the expanded capabilities of our automated
cellular processing tools to customers throughout the world."
AXP II, when utilized in combination with a companion,
single-use, cell separation set, provides automated, rapid and
reliable harvesting of stem and progenitor cells from collected
units of umbilical cord blood in a "functionally-closed," sterile
system. Upgrades to the original AXP system include enhanced
functionality, user interface and compatibility with newer
operating systems. Additionally, the AXP II features an improved
docking station and XpressTRAK® software to maintain
compliance with Current Good Manufacturing Practice (cGMP) and
Current Good Tissue Practice (cGTP) regulations.
About the AXP® II System
The AXP II System
is a proprietary, automated system for the isolation, collection
and storage of hematopoietic stem cell concentrates from cord
blood. Its functionality:
- automates the volume reduction process,
- provides consistent buffy coat concentration volumes,
- ensures high recoveries of mononuclear cells in a targeted
volume, and
- allows for simultaneously processing of multiple cord blood
units in one centrifuge.
The AXP II System includes the AXP II Device, AXP II Docking
Station, AXP Processing Bag Set,
XpressTRAK® software and accessories.
About CBR®
Founded in 1992, CBR is entrusted by parents with storing more than
875,000 cord blood and cord tissue samples for their children. As
part of the California Cryobank Life Sciences family, the
organization is dedicated to advancing the clinical application of
cord blood and cord tissue stem cells by partnering with
institutions to establish FDA-regulated clinical trials for
conditions that currently have no cure. To date, CBR has helped
more than 500 families use their cord blood stem cells for
established and experimental medical treatments in regenerative
medicine, more than any other family cord blood bank. CBR's goal is
to expand the potential scope of newborn stem cell therapies that
may be available to patients and their families. CBR is
headquartered in Los Angeles,
California and owns an 80,000 square foot laboratory in
Tucson, Arizona.
Cord Blood Registry is a registered trademark of CBR Systems,
Inc.
About ThermoGenesis
ThermoGenesis develops,
commercializes and markets a full suite of solutions for automated
clinical biobanking, point-of-care applications, and automation for
immuno-oncology. The company has developed an automated,
functionally-closed CAR-TXpress™ platform to
streamline the manufacturing process for the emerging CAR-T
immunotherapy market. For additional information, please visit:
www.ThermoGenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics
Inc. is a market leader in cell processing technologies and
autologous cell therapies for regenerative medicine. For more
information, visit: www.cescatherapeutics.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/americas-largest-cord-blood-bank-cbr-upgrading-to-thermogenesis-axp-ii-system-300889098.html
SOURCE Cesca Therapeutics Inc.
